ReviewTrends in parasitology2008
Flipping the paradigm on malaria transmission-blocking vaccines.
Review in Trends in parasitology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 93 citations in OpenAlex.
- Priming or Boosting Plasmodium falciparum Transmission-Blocking Responses With Recombinant Vaccines or Gametocyte Extract.The Journal of infectious diseases · 2025Article
- Article
- Advances in Non-Chemical Tools to Control Poultry Hematophagous Mites.Veterinary sciences · 2023Review
- Review
- Are malaria transmission-blocking vaccines acceptable to high burden communities? Results from a mixed methods study in Bo, Sierra Leone.Malaria journal · 2021Article
- Immunofocusing humoral immunity potentiates the functional efficacy of the AnAPN1 malaria transmission-blocking vaccine antigen.NPJ vaccines · 2021Article
- Progress towards the development of aExpert review of vaccines · 2021Review
- Article
- A Hetero-Multimeric Chitinase-ContainingFrontiers in cellular and infection microbiology · 2020Article
- Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination.Malaria journal · 2018Article
- Prevention and Control Strategies to Counter Zika Virus, a Special Focus on Intervention Approaches against Vector Mosquitoes-Current Updates.Frontiers in microbiology · 2018Review
- The fibrinogen-like domain of FREP1 protein is a broad-spectrum malaria transmission-blocking vaccine antigen.The Journal of biological chemistry · 2017Article
- M1 aminopeptidases as drug targets: broad applications or therapeutic niche?The FEBS journal · 2017Review
- Reduction of Mosquito Survival in Mice Vaccinated withBioMed research international · 2017Article
- Genome Investigations of Vector Competence in Aedes aegypti to Inform Novel Arbovirus Disease Control Approaches.Insects · 2016Review
- Arbovirosis and potential transmission blocking vaccines.Parasites & vectors · 2016Review
- An antibody against an Anopheles albimanus midgut myosin reduces Plasmodium berghei oocyst development.Parasites & vectors · 2016Article
- The Anopheles-midgut APN1 structure reveals a new malaria transmission-blocking vaccine epitope.Nature structural & molecular biology · 2015Article
- Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Differential roles of an Anopheline midgut GPI-anchored protein in mediating Plasmodium falciparum and Plasmodium vivax ookinete invasion.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The idea of malaria transmission-blocking vaccines (TBVs) surfaced more than two decades ago. Since then, the research paradigm focused on developing TBVs that target surface antigens of parasite sexual stages. Only recently has an effort emerged that flipped this paradigm, targeting antigens of the parasite's obligate invertebrate vector, the Anopheles mosquito. Here, we review the current state of knowledge of mosquito-based TBVs and discuss the utility of this approach for future vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.